Results 141 to 150 of about 4,909 (178)

Is hyperthermic intraperitoneal chemotherapy (HIPEC) safe for healthcare workers?

Surgical Oncology, 2017
During hyperthermic intraperitoneal chemotherapy (HIPEC), caregivers are exposed by different routes to cytotoxic drugs. This review proposes an overview of the safety of HIPEC by assessing existing data on protection procedures, biological and non-biological samples.
Rodier, Simon, Saint-Lorant, Guillaume, Guilloit, Jean-Marc, Palix, Agnès, Divanon, Fabienne, Sichel, François, Delépée, Raphaël   +6 more
openaire   +3 more sources

Cytoreductive Surgery and “Hyperthermic Intraperitoneal Chemotherapy (HIPEC)”

2016
For a long time malignant tumor manifestation of the peritoneum, peritoneal carcinomatosis (PC) was regarded as terminal. This meant that both medical and surgical palliation treatments came into question which aimed to keep quality of life as long as possible. These methods are known as “best supportive care.”
Markus Hirschburger, Winfried Padberg
openaire   +1 more source

Robotic-assisted cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)

Journal of Robotic Surgery, 2018
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is an appropriate treatment for select patients with peritoneal carcinomatosis. While most commonly performed through an open incision, the laparoscopic approach has been reported and offers short-term benefits.
Emmanuel Gabriel, Enrique Elli, Sanjay Bagaria, Nabil Wasif, Travis Grotz, John Stauffer, Pashtoon M. Kasi, Horacio Asbun   +7 more
openaire   +2 more sources

Operating personnel safety during the administration of Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Surgical Oncology, 2016
Cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is increasingly used in the treatment of peritoneal malignancies. The administration of HIPEC after complete cytoreduction offers the combination of the pharmacokinetic advantages inherent to the intraperitoneal delivery of cytotoxic chemotherapy, with the direct ...
Ioannis, Kyriazanos, Vasileios, Kalles, Anastasios, Stefanopoulos, John, Spiliotis, Faheez, Mohamed   +4 more
openaire   +2 more sources

Investigations on safety of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with Mitomycin C

European Journal of Surgical Oncology, 2006
Previous safety monitoring of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with Mitomycin C (MMC) did not demonstrate any detectable safety hazard to the personnel. Nevertheless, those results have been discussed controversially because of the methodological problems employed in the evaluation of potential exposure.
K, Schmid, M I, Boettcher, J O W, Pelz, T, Meyer, G, Korinth, J, Angerer, H, Drexler   +6 more
exaly   +3 more sources

The Role of Laparoscopy in Peritoneal Surface Malignancies Selected for Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Annals of Surgical Oncology, 2012
Cytoreductive surgery (CS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) was developed as locoregional treatment for primary or secondary peritoneal tumors. The role of laparoscopy over several stages of diagnosis and the treatment of the patients affected by peritoneal carcinomatosis and selected for CS + HIPEC shows some ...
SOMMARIVA, ANTONIO, Zagonel V, ROSSI, CARLO RICCARDO   +2 more
openaire   +2 more sources

[Importance of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer].

Bulletin du cancer, 2010
Hyperthermic intraperitoneal chemotherapy (HIPEC) represents a new treatment strategy aimed to improve outcome of patients with advanced ovarian cancer. Based on theoretical and experimental basis, HIPEC should stand as an effective treatment for ovarian cancer.
Gwénaël, Ferron, Alejandra, Martinez, Eliane, Mery, Denis, Querleu, Fabienne, Thomas, Etienne, Chatelut, Laurence, Gladieff   +6 more
openaire   +1 more source

Anesthesia for Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

2021
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an acceptable therapeutic modality for peritoneal surface malignancies. Such surgeries are challenging to anesthesiologists due to many concerns in the perioperative period related to CRS and HIPEC phases specifically.
openaire   +1 more source

Skin necrosis following hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C

BMJ Case Reports
This article describes the case of a man in the early 50s diagnosed with left-sided colon cancer with peritoneal metastasis, who underwent neoadjuvant chemotherapy, followed by laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). One week postoperatively, he developed a painful, erythematous rash over the left flank,
Emerik Arseneault-Monette, Kadhim Taqi, Lloyd Mack, Antoine Bouchard-Fortier   +3 more
openaire   +2 more sources

The Emerging Role of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Pancreatic Cancer

Journal of Surgical Oncology
ABSTRACTPeritoneal spread is a frequent cause of metastasis in both the synchronous and metachronous settings for patients with pancreatic cancer. Recent improvements in systemic chemotherapy for pancreatic cancer may now allow for the careful selection of patients with oligometastatic disease isolated to the peritoneum who may benefit from ...
Cornelius Thiels, Travis E. Grotz
openaire   +2 more sources